ANTONIO
CASADO HERRÁEZ

Profesor asociado de Ciencias de la Salud

Foto de ANTONIO

Foto de Antonio

Antonio
Jimeno

Antonio Jimeno-rekin lankidetzan egindako argitalpenak (5)

2016

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)
Targeted Oncology

2015

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Targeted Oncology, Vol. 10, Núm. 4, pp. 583-596

2014

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Journal of Clinical Oncology, Vol. 32, Núm. 4, pp. 320-326
Reply to B. Freidlin et al
Journal of Clinical Oncology

2012

EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials
European Journal of Cancer, Supplement, Vol. 10, Núm. 1, pp. 66-75